http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Choi, Joon-Sig,Choi, Min-Ji,Go, Gyeong-Su,Rhee, Byoung-Doo,KimPak, Young-Mi,Bang, In-Seok,Lee, Min-Hyung Korean Chemical Society 2006 Bulletin of the Korean Chemical Society Vol.27 No.9
It has been found that a number of diseases are associated with mutations in the mitochondrial DNA. Therapeutic gene delivery to mitochondria has been suggested as a clinical option for these diseases. In this study, we developed a gene carrier to mitochondria by the conjugation of mitochondrial leader peptide (LP) to polyethylenimine (PEI). Mitochondrial LP conjugated PEI (PEI-LP) was synthesized with low molecular weight PEI (2,000 Da, PEI2K). Gel retardation assay showed that PEI2K-LP formed complexes at a 1.0/1 weight ratio. In addition, PEI2K-LP protected DNA from the enzymatic degradation for at least 60 min, while naked DNA was completely degraded within 20 min. PEI2K-LP was compared with LP conjugated high molecular weight PEI (25,000 Da, PEI25K) in terms of toxicity and delivery efficiency. MTT assay showed that PEI2K-LP had much lower cytotoxicity than PEI25K-LP to 293 cells. In addition, cell-free DNA delivery assay showed that PEI2K-LP delivered more DNA to mitochondria at a 1.8/1 weight ratio than naked DNA or PEI. This result suggests that PEI2K-LP may be useful for the development of mitochondrial gene therapy system with lower cytotoxicity.
기억력 저하를 호소하는 노인들을 대상으로 INM176를 3개월간 임상시험한 후의 치료성적 및 부작용 평가 보고
김지혜,고선규,고효정,권영아,김성환,김재경,김태은,박재우,서민영,송영란,이인수,김도관 大韓神經精神醫學會 2003 신경정신의학 Vol.42 No.2
Objectives : We examined the effects of INM 176 (K-l107) compared with placebo on the cognitive functions of 92 old aged subjects with cognitive impairment. Methods : This was a prospective, 12 week, double-blind, Placebo-controlled clinical trial. The elderly who achieved a score of less than 25 points on the K-MMSE or showed a high risk of Alzheimer's disease from the 7-Minute Neurocognitive Screening Battery were considered to have objective impairment and were selected as subjects for this study. The subjects were randomized to placebo or INM 176 group. The outcome measures were from the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-Cog), the Instrumental Activities ofDaily Living (IADL) and the Korean Geriatric Depression Scale (KGDS) and two kinds of computerized priming tests. After setting the total error score in the Alzheimer's Disease Assessment Scale-Cognitive section (ADAS-cog) as the repeated measurement factor, an analysis of variance of the combined factor design was done between the placebo and INM 176 group. Results : The interaction effect of time (pre- and post-trial) and group (placebo and INM 176 group) was significant in the analysis of the ADAS-cog's total error score. The INM 176 group's total error score in the ADAS-cog decreased significantly (p<0.01), whereas the placebo group showed a slight increase. The mean changes in IADL and GDS from baseline scores favored in the INM 176 group than in the placebo group. Outcome changes ofADAS-cog, IADL, KGDS scores during the 12 week clinical trail ofINM 176 and placebo demonstrated favorable responses in the INM176 administered group. Conclusions : This is a preliminary clinical trial result of INM176 as a memory pill. Based on these results, INM176 may be a candidate molecule for the improvement of cognitive functions, including memory, Further clinical trial should demonstrate its efficacy.
A macrosomic baby born weighted 6.23kg from diabetic mother
( Ji Won Min ),( Deok Gyeong Kim ),( Sun Gyeong Kim ),( Hui Gyeong Seo ),( Yun Sook Kim ) 대한산부인과학회 2018 대한산부인과학회 학술대회 Vol.104 No.-
Antenatal precise diagnosis of fetal macrosomia is very difficult. Ultrasonographic diagnosis is very inaccurate for over 4 kg. A 28-year-old unmarried woman who had not got sufficient prenatal care visited the emergency room of our hospital. Although the expected delivery date was not accurate because she didnt have a proper prenatal care, it was estimated to be about 41 weeks. She had diagnosed with diabetic mellitus (DM) and she was severe preeclampsia. This was her 5th baby, the previous four children were all born vaginally. The estimated fetal body weight by ultrasonography was about 4.1kg. Since there was no fetal descent even 1 hour after the full cervical dilatation, we delivered a 6.23kg girl in an emergency cesarean section. We are reporting this case with the hope that it may contribute to clinical practice with diagnosing and managing macrosomia. Acknowledgements: This work was supported by the Soonchunhyang University Research Fund
Insecticidal activity of oriental medicinal plants against Myzus persicae
Ji Yun Min(민지윤),Jun Young Kim(김준영),Young Min Goo(구영민),Seung Kyu Ahn(안승규),Hyo Hyung Lee(이효형),Keon Hee Ko(고건희),Min Ji Kim(김민지),Yun Geun Kim(김윤근),Mi Young Yoon(윤미영),Gyeong Seon Kim(김경선),Kyeong Yeol Oh(오경 한국약용작물학회 2013 한국약용작물학회 학술대회논문집 Vol.2013 No.1
Consensus Update for Systemic Treatment of Atopic Dermatitis
( Ji Hyun Lee ),( Jung Eun Kim ),( Gyeong-Hun Park ),( Jung Min Bae ),( Ji Yeon Byun ),( Min Kyung Shin ),( Tae Young Han ),( Seung Phil Hong ),( Yong Hyun Jang ),( Hye One Kim ),( Chan Ho Na ),( Bark 대한피부과학회 2021 Annals of Dermatology Vol.33 No.6
Background: In 2015, the Korean Atopic Dermatitis Association (KADA) working group published consensus guidelines for treating atopic dermatitis (AD). Objective: We aimed to provide updated consensus recommendations for systemic treatment of AD in South Korea based on recent evidence and experience. Methods: We compiled a database of references from relevant systematic reviews and guidelines on the systemic management of AD. Evidence for each statement was graded and classified based on thestrength of the recommendation. Forty-two council members from the KADA participated in three rounds of voting to establish a consensus on expert recommendations. Results: We do not recommend long-term treatment with systemic steroids forpatients with moderate-to-severe AD due to the risk of adverse effects. We recommend treatment with cyclosporine or dupilumab and selective treatment with methotrexate or azathioprine for patients with moderate-to-severe AD. We suggest treatment with antihistamines as an option for alleviating clinical symptoms of AD. We recommend selective treatment with narrowband ultraviolet B for patients with chronic moderate-to-severe AD. We do not recommend treatment with oral antibiotics for patients with moderate-to-severe AD but who have no signs of infection. We did not reach a consensus on recommendations for treatment with allergen-specific immunotherapy, probiotics, evening primrose oil, orvitamin D for patients with moderate-to-severe AD. We also recommend educational interventions and counselling for patients with AD and caregivers to improve the treatment success rate. Conclusion: We look forward to implementing a new and updated consensus of systemic therapy in controlling patients with moderate-to-severe AD.